Purpose: Pain is a common symptom of knee OA. The presentation of the symptom is protean, and varies from person to person and from disease stage to disease stage. WOMAC pain sub scores assess a subject's pain while: 1) In bed; 2) Walking; 3) Climbing stairs; 4) Standing; and 5) Lying down. These five categories reflect, presumably, different etiologies of pain. To better understand the etiology of pain in these settings, the OAI has been capturing thousands of variables (variable is a specific clinical data) in OA patients; hopefully, evaluation of these variables will allow a better understanding of OA, and establish predictors of OA related pain. The objective of this work was to use automated wide association tools to determine which OAI variables, singularly or in association with other variables, best predict future OA related pain. Methods: The 4786 OAI enrolled subjects and the 1226 variables of the OAI baseline clinical datasets (OAI:0.2.2) and the 36 month WOMAC pain sub-score data (OAI:5.2.1) were explored in this study. Baseline variables with more than 10% of missing information were removed. Subjects with 36 month missing WOMAC pain data were removed. Therefore, only 4204 patients and 629 variables were included in this study. Furthermore, to explore the no-pain related sources of future knee pain all baseline pain related variables were removed. The max value from the left and right knee pain sub-scores were used as the outcome variable to be predicted by a five variable multidimensional nearest centroid classifier using BIOMATEC (Monterrey, Mexico). The top predictor variables of each pain sub-score were selected after generating 5000 models using a 33%, 67% split between training and testing sets. Once the top variables were selected, linear models and R software were used to get the significance of those variables in predicting the 36 month WOMAC pain scores. Results: All linear regression models were highly significant (p<1.0-10) with R2 ranging from 0.199 to 0.328. Left knee catch or hand up when moving, folate supplements, having a symptomatic knee, physical scale and right knee stiffness score predicted pain while lying down. Health limiting moderate activities, WOMAC knee stiffness, left knee KOOS symptoms and blood pressure predicted pain in Bed. Climbing stairs pain was predicted by lack of confidence in knees and WOMAC disability score. Health limiting moderate activities, left knee swelling, lack of confidence in knees and WOMAC stiffness score predicted pain while walking. Standing pain was predicted by KOOS symptom score and 400 meters walk time physical test. Conclusions: Wide association studies can be very helpful in data mining the OAI databases. These tools were used to explore models predictive of the 36 month pain sub scores and yielded highly predicting models. Therefore, three year pain prognosis is possible using clinical data. 1 Dept. of Orthop. Surg., Niigata Univ., Niigata, Japan; 2 Dept. of Orthop. Surg., Niigata Prefectural Central Hosp., Joetsu, Japan; 3 Dept. of Orthop. Surg., Saiseikai Niigata Daini Hosp., Niigata, Japan; 4 Dept. of Orthop. Surg., Niigata Rosai Hosp., Joetsu, Japan; 5 Ctr. for Transdisciplinary Res., Niigata Univ., Niigata, Japan; 6 Dept. of Orthop. Surg., Niigata Med. Ctr. Hosp., Niigata, Japan
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Purpose: Biochemical markers of cartilage degradation are important indices to evaluate knee osteoarthritis (OA). The correlation between radiological knee OA and urine CTX-II (C-terminal crosslinking telopeptide of collagen type II: uCTX-II) needs to be evaluated how this marker is useful in the health check-up in a large population-based study. Methods: We have performed the epidemiological knee survey in a rural Japanese population at the Matsudai district in Niigata Prefecture, Japan since 1979. In 2010 (6th survey), a cross-sectional study of biomarkers was conducted with informed consent. Urine specimens were collected from 942 subjects, and uCTX-II was measured using Urine CartiLaps EIA. The data more than 1000 ng/mmmol Cre were considered as outliers. Subjects with oral administration of bisphosphonate, fracture within a year, or TKA were excluded. Standing knee AP X-rays were obtained and graded according to the Kellgren-Lawrence (K-L) classification. The 60-to 79-yearold subjects were selected and then divided by gender (260 female and 276 male) and OA grade (K-L Grade 0,1, Grade 2, and Grade 3,4 groups). The levels of uCTX-II were compared between three OA grade groups using Kruskal-Wallis test and Mann-Whitney U-test. The subjects were stratified into quartiles based on the values of uCTX-II, and proportion of OA grades in each quartile was compared using chi-square test. In addition, to (Fig.1A) . In male subjects, OA G3,4 group had significantly higher uCTX-II values than G0,1 group or G2 group (Fig.1B) . Purpose: The purpose of this study was to evaluate the performance metrics of a new C2C sandwich immunoassay (IB-C2C-HUSA), including reproducibility and linearity as well as variation due to physical activity or food consumption, to inform biospecimen collection protocols in clinical trials. Type II collagen is the most abundant collagen in articular cartilage, providing tensile strength, and is cleaved by collagenases, resulting in the creation of a neoepitope at the C terminus of the 3 / 4 length fragment, detectable in human body fluids by the C2C competitive ELISA. Once this initial cleavage has occurred, proteases create subsequent degradation products containing the C-terminal neoepitope that are detectable in human urine. Methods: Forty participants with knee OA (20 patients for each of two cohorts) were admitted overnight for serial urine sampling to assess the variation of OA-related biomarkers. Urine samples were obtained on the evening (6-8PM) of Day 1 (T3; n¼34), prior to rising (8AM) from bed (T0; n¼34), 1 hr after rising (9AM) without food consumption (T1a; n¼20), 1-2 hr after rising (9-10AM) with food consumption (T1; n¼34), and at noon, 4 hr after rising (T2; n¼14). Urine C2C was measured using the new IB-C2C-HUSA and values were corrected for creatinine concentrations and reported as ng/mmol Cr. The linearity of the assay was determined by testing each urine sample at neat, 1:2, and 1:4 dilutions. The percent recovery was calculated as the adjusted concentration versus the adjusted concentration of the previous dilution. The acceptance criteria for linearity are between 70-130%. To assess for variation due to activity and food consumption across the cohorts, the biomarker concentrations at each time point for each subject were normalized to the mean concentration of the four time points for that individual. Results were analyzed using non-parametric Friedman's test with Dunn's post-hoc multiple comparison test. To compare the results of the newly formatted assay to the original C2C assay, correlation analyses of the IB-C2C-HUSA to C2C values measured previously in the same samples was performed. Statistical analyses were performed using GraphPad software and a p-value <0.05 was considered significant. Results: C2C was measurable in all urine samples using the new IB-C2C-HUSA and values from analysis of neat samples were used for 98.5 percent of the determinations. For samples that had concentrations higher than the highest standard (5000 pg/ml), a dilution factor of 1:2 was used to determine the final concentration. The standard curve was linear (R 2 ¼0.992) and the assay was linear from neat to 1:4 dilutions with a mean percent recovery of 126%. The mean concentrations +SD and range for the IB-C2C-HUSA biomarker at each time point (pg/ml) were as follows: T0: 1244+1055 (249-5246);T1a: 1635+1205 (344-5771); T1: 1871+1032 (443-4952); T2: 1074+ (239-3213); T3: 1043+814 (240-3845). Whereas C2C concentrations, uncorrected for urine creatinine, varied greatly within a day (Fig 1A) , C2C concentrations corrected for creatinine demonstrated no statistically significant variation of the biomarker with either activity (T1a) or with food consumption (T1) (Fig 1B) 
